Karyn A. Goodman, MD, of the University of Colorado School of Medicine, discusses initial study findings on PET scan–directed combined-modality therapy for esophageal cancer (Abstract 1).
Ian Chau, MD, of the Royal Marsden Hospital, discusses the continuum of care in esophageal and gastric cancers and the multiple active lines of treatment. Routine adoption of genomic testing may lead to further refinement of current treatment and more options in the future.
Cornelis van de Velde, MD, PhD, of Leiden University Medical Center, discusses the International Watch & Wait database, established to track evidence on organ-preserving strategies in patients with rectal cancer (Abstract 521).
Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).
Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses study findings on paclitaxel with and without RAD001 in patients with gastric cancer whose disease has progressed after therapy with a fluoropyrimidine/platinum-containing regimen (Abstract 4).
